USA Compression Partners, LP (USAC)

Revance Therapeutics Stock Forecast

Stock Price Forecast

The 4 analysts that cover Revance Therapeutics stock have a consensus rating of "Hold" and an average price target of $26.25, which forecasts a 13.24% increase in the stock price over the next year. The lowest target is $25 and the highest is $27.

Price Target: $26.25 (+13.24%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$25	$26.25	$27	$27
Change	+7.85%	+13.24%	+16.48%	+16.48%

* Price targets were last updated on Jun 23, 2025.

Analyst Ratings

The average analyst rating for Revance Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	0	0	0	0	0	0
Buy	1	1	1	1	0	0
Hold	3	3	3	3	3	3
Sell	0	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	4	5	5	5	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jeremy Tonet JP Morgan	JP Morgan	Sell Initiates $24 → $25	Sell	Initiates	$24 → $25	+7.85%	Jun 23, 2025
Jeremy Tonet JP Morgan	JP Morgan	Sell Maintains $23 → $24	Sell	Maintains	$23 → $24	+3.54%	Mar 11, 2025
Douglas Irwin Citigroup	Citigroup	Hold Maintains $24 → $27	Hold	Maintains	$24 → $27	+16.48%	Feb 25, 2025
Gabriel Moreen Mizuho	Mizuho	Hold Maintains $24 → $26	Hold	Maintains	$24 → $26	+12.17%	Feb 3, 2025
Elvira Scotto RBC Capital	RBC Capital	Hold Reiterates $27	Hold	Reiterates	$27	+16.48%	Nov 22, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

1.01B

Increased by 6.58%

from 950.45M

Revenue Next Year

1.06B

Increased by 4.94%

from 1.01B

EPS This Year

0.80

Increased by 10.85%

from 0.72

EPS Next Year

1.15

Increased by 44.46%

from 0.80

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	667.68M	632.65M	704.60M	846.18M	950.45M	1.01B	1.06B	1.11B
Revenue Growth	-4.39%	-5.25%	11.37%	20.09%	12.32%	6.58%	4.94%	4.14%
EPS	-6.65	-0.40	-0.19	0.20	0.72	0.80	1.15	1.47
EPS Growth	-	-	-	-	260.00%	10.85%	44.46%	27.12%
Forward PE	-	-	-	-	-	29.04	20.10	15.81
No. Analysts	-	-	-	-	-	7	7	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.0B	1.1B	1.2B
Avg	1.0B	1.1B	1.1B
Low	967.8M	1.0B	1.0B

Revenue Growth

Revenue Growth	2025	2026	2027
High	10.4%	9.8%	10.2%
Avg	6.6%	4.9%	4.1%
Low	1.8%	-0.3%	-2.6%

EPS Forecast

EPS	2025	2026	2027
High	0.87	1.56	1.88
Avg	0.80	1.15	1.47
Low	0.74	0.95	1.07

EPS Growth

EPS Growth	2025	2026	2027
High	21.0%	95.0%	63.1%
Avg	10.9%	44.5%	27.1%
Low	2.1%	19.1%	-7.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.